Ceiling Prices Of 915 Formulations Fixed: Govt

New Delhi : The government on Tuesday said that till July 17, ceiling prices have been fixed for 915 scheduled formulations. Out of the total, ceiling prices of 691 formulations have been fixed under the National List of Essential Medicines (NLEM) 2022 and 224 formulations under NLEM 2015, Union Minister of State for Chemicals and Fertilisers Bhagwanth Khuba said in a written reply to Rajya Sabha.

Besides, the retail price of around 2,450 new drugs under Drugs (Prices Control) Order, 2013 has been fixed till July 7, 2023, he noted.

The minister also stated that a total of 5,772 complaints alleging overcharging were received by drug pricing regulatory body NPPA over the five-year period ranging between 2018-19 and 2022-23.

Replying to a query regarding the Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs), Khuba said 9,512 outlets are now functional across the country.

The product basket of PMBJP presently comprises about 1,800 medicines and 285 surgical devices, covering all major therapeutic groups, he noted.

The government has fixed a target for opening 10,000 PMBJKs by March 2024.

Related Posts

WHO launches new primary health care course to strengthen health systems globally

Health is a human right – yet not everyone can access the health services they need, when and where they need them, without financial hardship. Primary health care (PHC) provides…

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

WHO launches new primary health care course to strengthen health systems globally

WHO launches new primary health care course to strengthen health systems globally

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert